# Characterization of Epilepsy Patients BEEP 2b

> **NCT02707965** · PHASE1 · COMPLETED · sponsor: **Food and Drug Administration (FDA)** · enrollment: 21 (actual)

## Conditions studied

- Epilepsy

## Interventions

- **DRUG:** Oxcarbazepine (brand name vs generic drugs)
- **DRUG:** Divalproex Sodium (brand name vs generic drugs)
- **DRUG:** Carbamazepine (brand name vs generic drugs)
- **DRUG:** Lamotrigine (brand name vs generic drugs)
- **DRUG:** levetiracetam (brand name vs generic drugs)
- **DRUG:** Topiramate (brand name vs generic drugs)
- **DRUG:** Zonisamide (brand name vs generic drugs)
- **DRUG:** Phenytoin sodium (brand name vs generic drugs)

## Key facts

- **NCT ID:** NCT02707965
- **Lead sponsor:** Food and Drug Administration (FDA)
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-08
- **Primary completion:** 2018-08-30
- **Final completion:** 2018-09-04
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2020-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02707965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02707965, "Characterization of Epilepsy Patients BEEP 2b". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02707965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*